Tonix Pharmaceuticals Holding Co（TNXP）在近日举办的2026年非阿片类疼痛治疗峰会上，正式公布了其创新药物Tonmya™（环苯扎林盐酸盐舌下片）的三期临床试验RESILIENT研究数据。该研究针对纤维肌痛症患者群体，结果显示Tonmya™在改善疼痛症状方面表现出显著疗效与良好安全性。此次数据发布进一步验证了舌下给药技术在非阿片类镇痛领域的应用潜力，为慢性疼痛治疗提供了新思路。
Tonix Pharmaceuticals Holding Co（TNXP）在近日举办的2026年非阿片类疼痛治疗峰会上，正式公布了其创新药物Tonmya™（环苯扎林盐酸盐舌下片）的三期临床试验RESILIENT研究数据。该研究针对纤维肌痛症患者群体，结果显示Tonmya™在改善疼痛症状方面表现出显著疗效与良好安全性。此次数据发布进一步验证了舌下给药技术在非阿片类镇痛领域的应用潜力，为慢性疼痛治疗提供了新思路。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.